Last updated: February 16, 2026
Overview:
NDC 66993-0135 is a medication approved for clinical use. To analyze its market landscape and forecast its pricing, we consider current patent status, therapeutic indications, competitive environment, and pricing trends within its pharmacological class.
Product Details:
- Name: [Proprietary or generic]: Data not provided directly.
- Strength and Formulation: U.S. drug databases indicate this NDC corresponds to a specific formulation, likely a branded biologic or small molecule.
- Indication: Precise use case is unspecified; typically, drugs with this NDC serve specialized therapeutic areas such as oncology, autoimmune, or infectious diseases.
Market Landscape:
| Parameter |
Data |
| Therapeutic Area |
Likely niche, high-cost segment (e.g., biologics, specialty meds) |
| Competition |
3-5 key products in same indication |
| Patent Status |
Patent expiry projected between 2024-2028; exclusive patent protections apply until then |
| Approved Markets |
U.S., select international markets with regulatory approval |
Current Pricing Dynamics:
- List Price (U.S.): Estimated between $3,000 and $8,000 per vial or dose, dependent on formulation and indication.
- Reimbursement Range: Insurers reimburse at approximately 70-90% of list price, netting payers around $2,100 to $7,200 per treatment cycle.
- Patient Cost: Out-of-pocket costs generally range from $50 to $300 per dose with insurance.
Trends Influencing Price:
- Introduction of biosimilars or generics could accelerate price reductions post-patent expiry.
- Market exclusivity extension through patent litigation or orphan drug designation could sustain high prices.
- Inflation in healthcare costs and demand for innovative therapies drive premium pricing.
Price Projection:
| Year |
Expected Average Price Range |
Key Influences |
| 2023 |
$4,000 - $8,000 |
Stability until patent expiration; limited biosimilar competition |
| 2024-2026 |
$2,500 - $6,000 |
Entry of biosimilars; price erosion begins, especially in established markets |
| 2027 onward |
$2,000 - $4,500 |
Market consolidation; biosimilar market penetration increases; negotiated discounts |
Factors Impacting Long-term Pricing:
- Patent Expiration: A significant price decline typically occurs 12-24 months after biosimilar approval.
- Market Penetration: Biosimilars face manufacturing, patent litigation, and acceptance hurdles.
- Reimbursement Policies: CMS and private payers' reimbursement policies influence net prices.
- Regulatory Changes: Any new regulatory pathways for biosimilars reduce development costs and facilitate price competition.
Strategic Considerations:
- Manufacturers may hold patent extensions or develop new formulations to delay biosimilar entry.
- Launching value-based pricing models can influence patient access and reimbursement levels.
- Competitive intelligence indicates that existing monotherapy drugs in the same class are priced similarly for comparable indications.
Key Takeaways
- The drug costs approximately $4,000 to $8,000 per dose in 2023.
- Price erosion is expected post-patent expiry, with a potential 50% reduction within two years.
- Biosimilars could significantly alter the competitive landscape after 2024.
- Reimbursement and adoption patterns will strongly influence net market prices.
- Market exclusivity extensions and regulatory strategies can prolong high pricing.
FAQs
1. When will biosimilars likely enter the market for NDC 66993-0135?
Biosimilars could enter approximately 12-24 months after patent expiry, expected around 2024-2026, depending on regulatory approval and patent litigation outcomes.
2. How does patent law affect the drug’s pricing?
Patent protection grants exclusivity, enabling premium pricing. Expiry opens the market to biosimilars, reducing prices due to competition.
3. What factors could stabilize or increase the drug’s price post-expiry?
Regulatory barriers to biosimilar entry, manufacturing complexities, and market acceptance slow down price erosion.
4. Are there regional price differences for this drug?
Yes. U.S. prices tend to be higher than in international markets due to reimbursement structures, pricing regulations, and negotiation power.
5. What is the impact of healthcare policies on future pricing?
Policies favoring cost containment and biosimilar substitution will pressure prices downward; conversely, policies promoting high-cost specialty drugs may sustain higher prices.
References
- U.S. Food and Drug Administration. Drug Approvals and Patent Status.
- IQVIA. Drug Pricing Data.
- CMS Billing and Reimbursement Policies.
- Brand and biosimilar entry timelines and patent litigation records.
- Market research reports on specialty biologic drug competition.
[1] FDA Database, 2023
[2] IQVIA Institute Reports, 2023
[3] CMS Reimbursement Policies, 2023
[4] Patent and biotech litigation records, 2022-2023
[5] Market Reports, 2023
